Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Exelixis Inc
(NQ:
EXEL
)
23.71
+0.42 (+1.80%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,634,762
Open
23.20
Bid (Size)
23.65 (9)
Ask (Size)
23.80 (3)
Prev. Close
23.29
Today's Range
23.19 - 23.78
52wk Range
18.08 - 24.34
Shares Outstanding
315,048,788
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Technical Signals Point to a Possible Breakout for EXELIXIS INC.
April 24, 2024
EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
Via
Chartmill
NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
April 24, 2024
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Via
Chartmill
Performance
YTD
-0.92%
-0.92%
1 Month
+0.04%
+0.04%
3 Month
+7.24%
+7.24%
6 Month
+19.27%
+19.27%
1 Year
+25.78%
+25.78%
More News
Read More
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
April 16, 2024
From
Exelixis, Inc.
Via
Business Wire
What Analysts Are Saying About Exelixis Stock
April 10, 2024
Via
Benzinga
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
March 29, 2024
Via
Chartmill
2 Stocks Under $30 to Buy and Hold
February 19, 2024
Via
The Motley Fool
Recap: Exelixis Q4 Earnings
February 06, 2024
Via
Benzinga
Earnings Scheduled For February 6, 2024
February 06, 2024
Via
Benzinga
3 Biotech Stocks to Buy on the Dip: March 2024
March 27, 2024
Via
InvestorPlace
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
March 23, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
March 09, 2024
Via
Talk Markets
2 Biotech Stocks to Buy Hand Over Fist in March
March 08, 2024
Via
The Motley Fool
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
March 06, 2024
Via
InvestorPlace
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
March 05, 2024
Via
Chartmill
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
March 02, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
February 27, 2024
From
Exelixis, Inc.
Via
Business Wire
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
February 23, 2024
Via
Benzinga
The 3 Best Biotech Stocks to Buy in February 2024
February 13, 2024
Via
InvestorPlace
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
Via
FinancialNewsMedia
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
February 13, 2024
Via
Chartmill
4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
February 10, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
3 Attractive Medical Stocks To Buy After Earnings
February 08, 2024
Via
Talk Markets
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
February 06, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
February 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.